RecruitingEarly Phase 1NCT07313618

Safety and Efficacy of a Single Suprachoroidal Injection of JWK010 Gene Therapy in Subjects With Oculocutaneous Albinism Type 1 (OCA1)

Studying Oculocutaneous albinism type 1

Last synced from ClinicalTrials.gov May 7, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: West China Hospital
Principal Investigator: Fang Lu
Department of Ophthalmology, West China Hospital, Sichuan University
Intervention: JWK010 gene therapy(genetic)
Enrollment: 18 enrolled
Eligibility: 5-12 years · All sexes
Timeline: 2025 – 2030

Study locations (1)

West China Hospital, Sichuan University, Chengdu, Sichuan, China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07313618 on ClinicalTrials.gov

← Back to all trials